Published in J Virol on August 04, 2010
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun (2013) 1.95
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med (2012) 1.94
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine (2011) 1.88
A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One (2012) 1.24
Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol (2012) 1.14
Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol (2011) 1.09
Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J Virol (2012) 1.01
Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther (2013) 1.00
Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J Immunol (2012) 1.00
Adenoviruses in lymphocytes of the human gastro-intestinal tract. PLoS One (2011) 0.98
Nonreplicating vectors in HIV vaccines. Curr Opin HIV AIDS (2013) 0.97
Viruses - from pathogens to vaccine carriers. Curr Opin Virol (2011) 0.96
Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors. J Virol (2014) 0.94
The influence of delivery vectors on HIV vaccine efficacy. Front Microbiol (2014) 0.92
Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol (2012) 0.92
Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines. Viruses (2012) 0.89
T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load. Eur J Immunol (2012) 0.88
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. Viruses (2015) 0.87
VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. J Virol (2014) 0.83
Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo. PLoS Pathog (2015) 0.83
The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. Vaccine (2015) 0.82
Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques. Mol Ther (2010) 0.82
Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines (2016) 0.82
Microbicides: a new hope for HIV prevention. Indian J Med Res (2011) 0.81
Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology (2014) 0.80
Can Viruses be Modified to Achieve Sustained Gene Transfer. Front Microbiol (2011) 0.80
Progress on adenovirus-vectored universal influenza vaccines. Hum Vaccin Immunother (2015) 0.80
Effect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vector. J Infect Dis (2011) 0.79
Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques. PLoS One (2015) 0.78
Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques. J Virol (2014) 0.78
Construction and characterization of E1- and E3-deleted adenovirus vectors expressing two antigens from two separate expression cassettes. Hum Gene Ther (2014) 0.77
Therapeutic vaccination against the rhesus lymphocryptovirus EBNA-1 homologue, rhEBNA-1, elicits T cell responses to novel epitopes in rhesus macaques. J Virol (2013) 0.77
The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses. J Leukoc Biol (2014) 0.76
Progress in the development of hepatitis C virus vaccines. Mol Ther (2012) 0.76
Immunogenicity and efficacy of a recombinant adenovirus expressing hemagglutinin from the H5N1 subtype of swine influenza virus in mice. Can J Vet Res (2014) 0.75
A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products. Hum Gene Ther Methods (2016) 0.75
Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget (2016) 0.75
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature (2008) 6.17
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol (2007) 4.54
CD46 is a cellular receptor for group B adenoviruses. Nat Med (2003) 4.35
The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol (1998) 4.26
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol (2003) 2.85
Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol (2008) 2.66
A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology (1996) 2.35
Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol (2002) 2.31
Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood (2007) 2.21
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin (2010) 2.12
Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med (2009) 2.10
Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology (1994) 2.04
Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis (2006) 1.99
Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun (2007) 1.85
Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther (2008) 1.84
Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med (2009) 1.82
Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol (2004) 1.66
Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol (2005) 1.29
Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine (2010) 1.27
Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum Gene Ther (2004) 1.23
Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin Vaccine Immunol (2009) 1.13
Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J Virol (2009) 0.99
A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther (2007) 0.96
Future paths for HIV vaccine research: Exploiting results from recent clinical trials and current scientific advances. Curr Opin Mol Ther (2010) 0.91
A single immunization with a recombinant canine adenovirus type 2 expressing the seoul virus Gn glycoprotein confers protective immunity against seoul virus in mice. Vaccine (2009) 0.84
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature (2000) 47.15
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J Struct Biol (1996) 22.89
A protein interaction map of Drosophila melanogaster. Science (2003) 20.06
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 11.90
A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet (1997) 10.93
Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell (1992) 9.19
A multiprotein mediator of transcriptional activation and its interaction with the C-terminal repeat domain of RNA polymerase II. Cell (1994) 8.44
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature (2001) 7.44
Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science (1997) 7.31
Nucleotide sequence of an RNA polymerase binding site from the DNA of bacteriophage fd. Proc Natl Acad Sci U S A (1975) 7.14
An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem (1999) 6.88
Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke (2001) 6.61
RSC, an essential, abundant chromatin-remodeling complex. Cell (1996) 6.17
Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science (1997) 6.00
BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 5.99
The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci U S A (2004) 5.87
A simple method for clinical assay of superoxide dismutase. Clin Chem (1988) 5.66
Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs. Mol Cell (1998) 5.60
Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum (2001) 5.36
Genetic diversity and disease control in rice. Nature (2000) 5.34
Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J Virol (1992) 5.19
Spin-torque switching with the giant spin Hall effect of tantalum. Science (2012) 5.18
Extensive variation of human immunodeficiency virus type-1 in vivo. Nature (1988) 5.02
Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet (1998) 4.67
Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke (2001) 4.64
Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A (1995) 4.54
Elongator, a multisubunit component of a novel RNA polymerase II holoenzyme for transcriptional elongation. Mol Cell (1999) 4.49
Femtosecond electronic response of atoms to ultra-intense X-rays. Nature (2010) 4.46
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene (2008) 4.43
Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev (1994) 4.30
The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol (1998) 4.26
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res (1999) 4.20
Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet (2000) 4.17
Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Curr Biol (2001) 4.16
A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell (2001) 3.97
Pax6 activity in the lens primordium is required for lens formation and for correct placement of a single retina in the eye. Genes Dev (2000) 3.85
Manifestation of the limb prepattern: limb development in the absence of sonic hedgehog function. Dev Biol (2001) 3.82
A novel histone acetyltransferase is an integral subunit of elongating RNA polymerase II holoenzyme. Mol Cell (1999) 3.80
Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest (2001) 3.79
Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat Genet (2000) 3.72
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Secondhand-smoke story goes up in flames. CMAJ (1998) 3.68
Auxin-induced expression of the soybean GH3 promoter in transgenic tobacco plants. Plant Mol Biol (1991) 3.67
Green fluorescent protein as a noninvasive intracellular pH indicator. Biophys J (1998) 3.61
Significance of premature stop codons in env of simian immunodeficiency virus. J Virol (1989) 3.60
Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol (1990) 3.56
A model of protein synthesis based on cryo-electron microscopy of the E. coli ribosome. Nature (1995) 3.56
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol (2005) 3.56
Is routine indwelling catheterisation of the bladder for caesarean section necessary? A systematic review. BJOG (2010) 3.54
A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. Nat Genet (2001) 3.52
A massive binary black-hole system in OJ 287 and a test of general relativity. Nature (2008) 3.50
Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum (1996) 3.40
Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced apoptosis. Cell (2000) 3.39
A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol (1993) 3.38
Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3'-end processing machinery. EMBO J (1999) 3.35
Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays. Nat Biotechnol (1998) 3.29
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (1999) 3.28
Generating yeast transcriptional activators containing no yeast protein sequences. Nature (1991) 3.21
Geminivirus strain demarcation and nomenclature. Arch Virol (2008) 3.21
A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res (1999) 3.19
Retracted Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet (2005) 3.13
Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur Heart J (2002) 3.09
Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol (2000) 3.07
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Three human transforming genes are related to the viral ras oncogenes. Proc Natl Acad Sci U S A (1983) 3.06
A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet (2004) 3.05
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial. Brain (2008) 2.99
Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol (2001) 2.93
Characterization of a multicomponent receptor for GDNF. Nature (1996) 2.92
The C. elegans zyg-1 gene encodes a regulator of centrosome duplication with distinct maternal and paternal roles in the embryo. Cell (2001) 2.92
Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. N Engl J Med (2016) 2.89
Antiviral RNA interference in mammalian cells. Science (2013) 2.89
Replication-defective vector based on a chimpanzee adenovirus. J Virol (2001) 2.86
Schistosomiasis in the People's Republic of China: prospects and challenges for the 21st century. Clin Microbiol Rev (2001) 2.85
Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci (2001) 2.84
CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell (1992) 2.83
Genetic properties of chromosomally integrated 2 mu plasmid DNA in yeast. Cell (1982) 2.78
Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet (2001) 2.77
Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med (1999) 2.74
Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol (2001) 2.72
Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene (2007) 2.68
Locus of enterocyte effacement from Citrobacter rodentium: sequence analysis and evidence for horizontal transfer among attaching and effacing pathogens. Infect Immun (2001) 2.68
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia (2006) 2.66
Simian immunodeficiency virus from African green monkeys. J Virol (1988) 2.65
Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol (1997) 2.64
Hyperammonaemia and Helicobacter pylori. Lancet (1995) 2.59
Cancer trial enrollment after state-mandated reimbursement. J Natl Cancer Inst (2004) 2.56
Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther (2004) 2.55
Comparison of simian immunodeficiency virus isolates. Nature (1988) 2.55
Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet (2001) 2.55
Disease specificity of nondefective Friend and Moloney murine leukemia viruses is controlled by a small number of nucleotides. J Virol (1987) 2.53
Identification of linear DNA sequences that specifically bind the adeno-associated virus Rep protein. J Virol (1994) 2.52
Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol Endocrinol (1997) 2.51
Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol (1996) 2.51